Anna M Sailer1, Patricia J Nelemans2, Trevor J Hastie3, Anne S Chin4, Mark Huininga5, Peter Chiu6, Michael P Fischbein6, Michael D Dake7, D Craig Miller6, G W Schurink5, Dominik Fleischmann8. 1. Department of Radiology, Stanford University School of Medicine, Stanford, Calif; Department of Radiology, Maastricht University Medical Center, Maastricht, The Netherlands. 2. Department of Epidemiology, Maastricht University Medical Center, Maastricht, The Netherlands. 3. Department of Biomedical Data Sciences, Stanford University School of Medicine, Stanford, Calif; Department of Statistics, Stanford University, Stanford, Calif. 4. Department of Radiology, Stanford University School of Medicine, Stanford, Calif. 5. Department of Vascular Surgery, Maastricht University Medical Center, Maastricht, The Netherlands. 6. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, Calif. 7. Department of Cardiothoracic Surgery, Stanford University School of Medicine, Stanford, Calif; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, Calif. 8. Department of Radiology, Stanford University School of Medicine, Stanford, Calif; Stanford Cardiovascular Institute, Stanford University School of Medicine, Stanford, Calif. Electronic address: d.fleischmann@stanford.edu.
Abstract
BACKGROUND: Patients with Stanford type B aortic dissections (ADs) are at risk of long-term disease progression and late complications. The aim of this study was to evaluate the natural course and evolution of acute type B AD and intramural hematomas (IMHs) in patients who presented without complications during their initial hospital admission and who were treated with optimal medical management (MM). METHODS: Databases from 2 aortic centers in Europe and the United States were used to identify 136 patients with acute type B AD (n = 92) and acute type B IMH (n = 44) who presented without complications during their index admission and were treated with MM. Computed tomography angiography scans were available at onset (≤14 days) and during follow-up for those patients. Relevant data, including evidence of adverse events during follow-up (AE; defined according to current guidelines), were retrieved from medical records and by reviewing computed tomography scan images. Aortic diameters were measured with dedicated 3-dimensional software. RESULTS: The 1-, 2-, and 5-year event-free survival rates of patients with type B AD were 84.3% (95% confidence interval [CI], 74.4-90.6), 75.4% (95% CI, 64.0-83.7), and 62.6% (95% CI, 68.9-73.6), respectively. Corresponding estimates for IMH were 76.5% (95% CI, 57.8-87.8), 76.5% (95% CI, 57.8-87.8), and 68.9% (95% CI, 45.2-83.9), respectively. In patients with type B AD, risk of an AE increased with aortic growth within the first 6 months after onset. A diameter increase of 5 mm in the first half year was associated with a relative risk for AE of 2.29 (95% CI, 1.70-3.09) compared with the median 6 months' growth of 2.4 mm. In approximately 60% of patients with IMH, the abnormality resolved within 12 months and in the patients with nonresolving IMH, risk of an adverse event was greatest in the first year after onset and remained stable thereafter. CONCLUSIONS: More than one third of patients with initially uncomplicated type B AD suffer an AE under MM within 5 years of initial diagnosis. In patients with nonresolving IMH, most adverse events are observed in the first year after onset. In patients with type B AD an early aortic growth is associated with a greater risk of AE.
BACKGROUND:Patients with Stanford type B aortic dissections (ADs) are at risk of long-term disease progression and late complications. The aim of this study was to evaluate the natural course and evolution of acute type B AD and intramural hematomas (IMHs) in patients who presented without complications during their initial hospital admission and who were treated with optimal medical management (MM). METHODS: Databases from 2 aortic centers in Europe and the United States were used to identify 136 patients with acute type B AD (n = 92) and acute type B IMH (n = 44) who presented without complications during their index admission and were treated with MM. Computed tomography angiography scans were available at onset (≤14 days) and during follow-up for those patients. Relevant data, including evidence of adverse events during follow-up (AE; defined according to current guidelines), were retrieved from medical records and by reviewing computed tomography scan images. Aortic diameters were measured with dedicated 3-dimensional software. RESULTS: The 1-, 2-, and 5-year event-free survival rates of patients with type B AD were 84.3% (95% confidence interval [CI], 74.4-90.6), 75.4% (95% CI, 64.0-83.7), and 62.6% (95% CI, 68.9-73.6), respectively. Corresponding estimates for IMH were 76.5% (95% CI, 57.8-87.8), 76.5% (95% CI, 57.8-87.8), and 68.9% (95% CI, 45.2-83.9), respectively. In patients with type B AD, risk of an AE increased with aortic growth within the first 6 months after onset. A diameter increase of 5 mm in the first half year was associated with a relative risk for AE of 2.29 (95% CI, 1.70-3.09) compared with the median 6 months' growth of 2.4 mm. In approximately 60% of patients with IMH, the abnormality resolved within 12 months and in the patients with nonresolving IMH, risk of an adverse event was greatest in the first year after onset and remained stable thereafter. CONCLUSIONS: More than one third of patients with initially uncomplicated type B AD suffer an AE under MM within 5 years of initial diagnosis. In patients with nonresolving IMH, most adverse events are observed in the first year after onset. In patients with type B AD an early aortic growth is associated with a greater risk of AE.
Authors: Anthony L Estrera; Charles C Miller; Jennifer Goodrick; Eyal E Porat; Paul E Achouh; Jayesh Dhareshwar; Riad Meada; Ali Azizzadeh; Hazim J Safi Journal: Ann Thorac Surg Date: 2007-02 Impact factor: 4.330
Authors: Christoph A Nienaber; Stephan Kische; Hervé Rousseau; Holger Eggebrecht; Tim C Rehders; Guenther Kundt; Aenne Glass; Dierk Scheinert; Martin Czerny; Tilo Kleinfeldt; Burkhart Zipfel; Louis Labrousse; Rossella Fattori; Hüseyin Ince Journal: Circ Cardiovasc Interv Date: 2013-08-06 Impact factor: 6.546
Authors: Raimund Erbel; Victor Aboyans; Catherine Boileau; Eduardo Bossone; Roberto Di Bartolomeo; Holger Eggebrecht; Arturo Evangelista; Volkmar Falk; Herbert Frank; Oliver Gaemperli; Martin Grabenwöger; Axel Haverich; Bernard Iung; Athanasios John Manolis; Folkert Meijboom; Christoph A Nienaber; Marco Roffi; Hervé Rousseau; Udo Sechtem; Per Anton Sirnes; Regula S von Allmen; Christiaan J M Vrints Journal: Eur Heart J Date: 2014-08-29 Impact factor: 29.983
Authors: Christopher A Durham; Richard P Cambria; Linda J Wang; Emel A Ergul; Nathan J Aranson; Virendra I Patel; Mark F Conrad Journal: J Vasc Surg Date: 2015-02-03 Impact factor: 4.268
Authors: Joon Bum Kim; Kibeom Kim; Mark E Lindsay; Thomas MacGillivray; Eric M Isselbacher; Richard P Cambria; Thoralf M Sundt Journal: Circulation Date: 2015-09-02 Impact factor: 29.690
Authors: Rana O Afifi; Harleen K Sandhu; Samuel S Leake; Mina L Boutrous; Varsha Kumar; Ali Azizzadeh; Kristofer M Charlton-Ouw; Naveed U Saqib; Tom C Nguyen; Charles C Miller; Hazim J Safi; Anthony L Estrera Journal: Circulation Date: 2015-08-25 Impact factor: 29.690
Authors: Molly E Roseland; Yunus Ahmed; Joost A van Herwaarden; Frans L Moll; Bo Yang; Himanshu J Patel; Nicholas S Burris Journal: Interact Cardiovasc Thorac Surg Date: 2021-08-18
Authors: Juliet Blakeslee-Carter; Hellen A Potter; Charles A Banks; Marc Passman; Benjamin Pearce; Graeme McFarland; Sukgu M Han; Salvatore Scali; Gregory A Magee; Emily Spangler; Adam W Beck Journal: J Vasc Surg Date: 2022-03-08 Impact factor: 4.860
Authors: Karlijn B Rombouts; Tara A R van Merrienboer; Johannes C F Ket; Natalija Bogunovic; Jolanda van der Velden; Kak Khee Yeung Journal: Eur J Clin Invest Date: 2021-11-21 Impact factor: 5.722